HU student wins Kaye Prize

Nir Qvit has developed a drug-delivery method by designing Lego-like molecules to halt cell growth.

By
June 8, 2006 02:04
1 minute read.
HU student wins Kaye Prize

legos 88. (photo credit: )

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Hebrew University doctoral student Nir Qvit has been awarded a Kaye Prize for Innovation for his development of a drug-delivery method that delivers medicine to targeted cells by designing specific Lego-like molecular structures called SIB (small integrated building blocks). Qvit, 34, will receive the prestigious science prize along with other winners Tuesday, during next week's 69th meeting of the university's board of governors. Qvit has demonstrated that it is possible to significantly increase the efficiency of drug delivery by designing specific molecular structures composed of pharmaceutically effective peptides (small protein molecules) that are attached to tailor-made, geometric-like structures called "scaffolding." Each scaffold is individually designed to combine the peptides to form an effective medicinal combination that will bind to the receptors of targeted cells. Qvit said his process was somewhat analogous to building various kinds of structures through the use of Lego. Qvit, who studies under Prof. Chaim Gilon of the organic chemistry department, has shown, for example, that with a particular combination of peptides and scaffold design, it is possible to create a synthetic molecule that will bind to the IGF-1 (insulin-like growth factor-1) receptor. IGF-1 is a protein that plays a critical role in the proliferation of many cancers, including prostate, lung, breast, colon and brain cancers. The binding of the molecule to the receptor inhibits the activation of the IGF-1 protein in the cells, thus halting the cancerous growth. Using this process of "combinational chemistry," involving peptides and scaffold design, Qvit says that many different types of molecules can be built to reach targeted cells, offering hope for the treatment of cancer and other diseases, without harming healthy cells. The Kaye Innovation Awards have been given annually since 1994. British pharmaceutical industrialist Isaac Kaye established the awards to encourage Hebrew University faculty, staff, and students to develop innovative methods and inventions with good commercial potential that will benefit the university and society.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

[illustrative photo]
September 24, 2011
Diabetes may significantly increase risk of dementia

By UNIVERSITY OF MICHIGAN HEALTH SYSTEM